Cytokines, Chemokines & Receptors

Cat. No.

AT1290

Anti-TGFb1 Antibody

The Anti-TGFb1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Transforming Growth Factor Beta 1 (TGFb1). This antibody comprises a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 145 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the biological activities and regulatory mechanisms of TGFb1.

Cat. No.

AT1305

Anti-IL-21 Antibody

Cat. No.

AT1322

CAS No.

2622900-74-5

Picankibart

Picankibart is a monoclonal antibody of the IgG1κ subtype, derived from mouse sources, specifically designed to target IL23A. This antibody is engineered for high specificity and affinity towards the interleukin-23 alpha subunit, making it an essential tool for research focused on inflammatory pathways and immune response regulation.

Cat. No.

AT1336

CAS No.

2097104-58-8

Spesolimab

Synonyms: BI 655130

Spesolimab (BI 655130) is a humanized IgG1κ monoclonal antibody derived from mouse sources, targeting the interleukin-36 receptor (IL-36R). IL-36 is critical in mediating immune responses, and Spesolimab has shown potential efficacy in clinical studies for the treatment of palmoplantar pustulosis (PPP). The therapeutic action of Spesolimab includes the modulation of biomarkers linked to innate immunity and Th1/Th17 and neutrophil pathways, suggesting its role in altering inflammatory processes. This antibody is currently under investigation for its therapeutic potential and mechanism of action in immune-mediated dermatological conditions.

Cat. No.

AT1348

CAS No.

1688648-13-6

Licaminlimab

Synonyms: OCS-02

Licaminlimab (OCS-02) is a single-chain antibody fragment specifically targeting TNF alpha, a pro-inflammatory cytokine predominantly secreted by macrophages and monocytes. This monoclonal antibody fragment is designed to neutralize TNF alpha, thereby modulating inflammatory responses. It is applicable in research focused on the pathophysiology and treatment of diseases characterized by excessive inflammation.

Cat. No.

AT1366

AV-380

AV-380 is a humanized IgG1 monoclonal antibody that specifically targets Growth Differentiation Factor 15 (GDF15). This antibody is designed for high specificity and affinity in binding to GDF15, making it an essential tool for research focused on understanding the role of GDF15 in various physiological and pathological processes. AV-380 is suitable for a range of experimental applications, including but not limited to, flow cytometry, Western blotting, and immunohistochemistry.

Cat. No.

AT1368

Anti-CXCL12/SDF1a Antibody

The Anti-CXCL12/SDF1a Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CXCL12/SDF1a. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For isotype control, reference is made to the Human IgG1 kappa, Isotype Control, ensuring accurate experimental comparisons. This product is essential for research focusing on the biological pathways and interactions involving CXCL12/SDF1a, which are critical in immunological signaling and cellular migration processes.

Cat. No.

AT1370

LY3022859 (IMC-TR1)

Synonyms: IMC-TR1

LY3022859 (IMC-TR1) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TGFβR2. This antibody is comprised of a human IgG1 type heavy chain and a human κ-type light chain, with a predicted molecular weight of 143 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Cat. No.

AT1383

Anti-IFNγ Antibody (B133.5)

The Anti-IFNγ Antibody (B133.5) is a chimeric mouse IgG1 monoclonal antibody that specifically targets human interferon gamma (IFNγ). This antibody is ideal for use in various immunological assays, including ELISA, Western blot, and immunohistochemistry, to accurately detect and quantify IFNγ levels. For accurate experimental controls, it is recommended to use Mouse IgG1 kappa, Isotype Control.

Cat. No.

AT1398

CAS No.

2639874-57-8

Temtokibart

Synonyms: ARGX-112

Temtokibart is a humanized IgG1λ2 monoclonal antibody that specifically targets the IL22RA1 receptor. This antibody is uniquely expressed by cells deficient in the glutamine synthetase gene, making it an essential tool for research focused on signaling pathways involving the IL-22 receptor. Temtokibart is ideal for studies investigating the role of IL22RA1 in various biological processes and diseases.

Cat. No.

AT1408

CAS No.

1085337-57-0

Mavrilimumab

Synonyms: CAM 3001

Mavrilimumab (CAM 3001) is a monoclonal antibody designed to target and bind specifically to the α subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. By attaching to this subunit, Mavrilimumab effectively inhibits the downstream intracellular signaling pathways activated by GM-CSF. This interaction is crucial, as GM-CSF is implicated as a potential mediator in the exacerbation of inflammatory responses that can lead to respiratory failure and mortality. This antibody is particularly relevant in research focused on inflammatory diseases and immune response regulation.

Cat. No.

AT1415

CAS No.

2750248-93-0

Nolavetbart

Nolavetbart is a human IgG2 κ monoclonal antibody targeting the IL31RA receptor in the Canlupfam species. For accurate experimental control, it is recommended to use Human IgG2 kappa as an isotype control.

Cat. No.

AT1422

CAS No.

285985-06-0

Lerdelimumab

Synonyms: CAT-152

Lerdelimumab (CAT-152) is a recombinant human monoclonal antibody of the IgG4 subclass that specifically targets transforming growth factor-beta 2 (TGF-β2). This antibody is utilized in research as an anti-scarring agent, particularly in studies related to glaucoma. Its mechanism of action involves neutralizing the biological activity of TGF-β2, a cytokine implicated in the pathogenesis of fibrosis and scarring.

Cat. No.

AT1432

SIM-0235

SIM-0235 is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody designed to specifically target and inhibit TNFR2 (Tumor Necrosis Factor Receptor 2). For experimental consistency and control, it is recommended to use Human IgG1 kappa as an isotype control. This product is pivotal for research focused on the modulation of immune responses and inflammation, particularly in studies related to cancer and autoimmune diseases.

Cat. No.

AT1433

CDP-484

CDP-484 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-1 beta (IL-1β). This antibody is constructed from a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, with an estimated molecular weight of 145.74 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. CDP-484's specificity and affinity for IL-1β make it an essential tool for research focused on inflammation, immune response, and related pathological conditions.

Cat. No.

AT1440

AMG-108

Synonyms: MEDI 8968

AMG-108 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting IL-1R1/CD121a. This antibody consists of a human IgG2 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of approximately 150 kDa. For experimental controls, the Human IgG2 kappa, Isotype Control is recommended.

Cat. No.

AT1449

hu14.18 (K322A)

Bermekimab (MABp1) is a human monoclonal antibody designed to specifically target and neutralize interleukin-1 alpha (IL-1α). By inhibiting this cytokine, Bermekimab effectively reduces tumor-associated inflammation, offering potential therapeutic benefits in the management of cancer-related inflammatory processes.

Cat. No.

AT1450

CAS No.

1401965-15-8

Bermekimab

Synonyms: MABp1

Bermekimab (MABp1) is a human monoclonal antibody designed to specifically target and neutralize interleukin-1 alpha (IL-1α). By inhibiting this cytokine, Bermekimab effectively reduces tumor-associated inflammation, offering potential therapeutic benefits in the management of cancer-related inflammatory processes.

Cat. No.

AT1453

BT-063

BT-063 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting interleukin-10 (IL-10). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.74 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1455

CAS No.

1174395-19-7

Brodalumab

Synonyms: AMG 827; KHK4827

Brodalumab (AMG 827) is a humanized IgG2 monoclonal antibody targeting the interleukin-17 receptor. This antibody is utilized in research focused on understanding and treating moderate-to-severe plaque psoriasis and rheumatoid arthritis. Brodalumab's mechanism involves blocking the activity of interleukin-17 (IL-17), a cytokine that plays a critical role in mediating inflammatory and immune responses.

Cat. No.

AT1470

CAS No.

948564-73-6

Fresolimumab

Synonyms: GC1008

Fresolimumab (GC1008) is a human monoclonal antibody designed to target and neutralize all active mammalian subtypes of Transforming Growth Factor-beta (TGF-β). It exhibits a high binding affinity to TGF-β2, with a dissociation constant (Kd) of 1.8 nM, indicating robust interaction with this cytokine. When conjugated with the radiolabel 89Zr, Fresolimumab serves as a valuable tool for Positron Emission Tomography (PET) analysis, facilitating the study of TGF-β expression, antibody biodistribution, and organ-specific uptake. This antibody is extensively applicable in research focused on cancer, fibrosis, osteogenesis imperfecta, and kidney disease, providing insights into the pathophysiological roles of TGF-β in these conditions.

Cat. No.

AT1487

GSK-679586

GSK-679586 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-13 (IL-13). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Cat. No.

AT1490

CAS No.

3021525-26-5

Lasrekibart

Lasrekibart is a humanized monoclonal antibody designed to selectively target human interleukin 5 (IL-5). By binding specifically to IL-5, Lasrekibart effectively blocks the interaction between IL-5 and its receptor, thereby exerting immunosuppressive and anti-inflammatory effects. This antibody is particularly valuable for research into allergic and inflammatory diseases, including asthma, offering potential insights into disease mechanisms and therapeutic avenues.

Cat. No.

AT1493

CAS No.

2375835-91-7

Lusvertikimab

Synonyms: OSE-127

Lusvertikimab (OSE-127) is a humanized monoclonal antibody that targets the interleukin-7 receptor (IL7R). This antibody uniquely binds to IL7R without being internalized by the target cells, effectively inhibiting IL7R heterodimerization and the subsequent downstream signaling pathways. Lusvertikimab demonstrates anti-leukemic properties and holds significant potential for research in B cell precursor acute lymphoblastic leukemia (BCP-ALL), making it a valuable tool for studies aimed at understanding and potentially treating this condition.

Cat. No.

AT1494

CAS No.

220651-94-5

Ruplizumab

Synonyms: BG 9588; Anti-Human CD40L Recombinant Antibody

Ruplizumab (BG 9588) is a humanized IgG1κ monoclonal antibody targeting CD40 ligand (CD40L), a member of the TNF receptor superfamily. This antibody is designed for the investigation of its therapeutic potential in systemic lupus erythematosus (SLE). Ruplizumab may facilitate the study of CD40L interactions and signaling pathways in immune response regulation, providing insights into the pathogenesis and treatment of SLE.